news

pharma& is a rapidly growing, internationally oriented company in a very exciting moment of expansion. In this section of the website, we regularly share our news with you.

31/10/2022

pharma& Schweiz GmbH (“pharma&”) is proud to announce to have acquired all of the remaining rights of Farydak^® (Panobinostat) from Secura Bio to secure long-term demand for a well-established therapy option used for the treatment of multiple myeloma.

31/01/2022

We are proud to announce that we closed an agreement with Astellas Deutschland GmbH, (a subsidiary of Astellas Pharma Inc.) on December 31^st 2021 to acquire Astellas’ worldwide rights* of Bendamustine commercialized under the brand names Levact^®, Ribomustin^® and others, securing access and continuous supply for patients benefitting from this well-established and distinguished therapy option.

For any inquiries, please contact us at contact@pharmaand.com.

*) excluding Marketing Authorizations in a small number of markets, including Morocco which is subject to merger clearance.